問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


MacKay Memorial Hospital (在職)

Division of Hematology & Oncology

Division of Thoracic Surgery

Division of Thoracic Medicine

MacKay Memorial Hospital

Division of Thoracic Medicine

更新時間：2023-09-19

蘇健
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

19Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蘇健

List

35Cases

2020-04-01 - 2025-11-26

Phase III

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Not yet recruiting2Sites

Recruiting4Sites

Terminated1Sites

2020-05-12 - 2025-12-31

Phase III

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Not yet recruiting6Sites

Recruiting2Sites

2020-09-15 - 2025-10-08

Phase II

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting6Sites

2022-02-01 - 2029-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Recruiting9Sites

2022-04-01 - 2028-09-30

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Not yet recruiting8Sites

2023-12-01 - 2031-05-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
11Sites

Recruiting11Sites

2024-04-15 - 2033-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
12Sites

Not yet recruiting11Sites

2024-05-01 - 2033-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Not yet recruiting8Sites

2026-02-23 - 2030-03-31

Phase I

Active
AN INTERVENTIONAL OPEN-LABEL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF PF-08634404 IN COMBINATION WITH DIFFERENT ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

  • Condition/Disease

    Advanced/Metastatic Non-Small Cell Lung Cancer

  • Test Drug

    輸注液 注射用凍晶粉末 注射用凍晶粉末

Participate Sites
6Sites

Not yet recruiting6Sites

2026-03-01 - 2043-12-31

Phase III

Active
A Phase 3, Randomized, Double-blind Study of Adjuvant MK-1084 Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus Adjuvant Placebo Plus MK-3475A in Participants With Completely Resected Stage IIA-IIIB (N2), KRAS G12C-mutant Non-small Cell Lung Cancer Following Receipt of Either Neoadjuvant Pembrolizumab Plus Chemotherapy or Adjuvant Chemotherapy (KANDLELIT-013)

  • Condition/Disease

    Non-small Cell Lung Cancer

  • Test Drug

    錠劑 皮下注射劑

Participate Sites
5Sites

Recruiting5Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB